<table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.26801.021</object-id><label>Table 1.</label><caption><p>The means and SEM for each experiment for PD patients and HC on all measures taken. Within each experiment, one-way ANOVAs were run between PD patients and HC (&#967;<sup>2</sup> for the genders), and paired t-tests for the comparisons between patients ON and OFF medication for the UPDRS. MMSE scores from experiment 1 were converted to MoCA scores for comparison. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.26801.021">http://dx.doi.org/10.7554/eLife.26801.021</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th>Experiment</th><th colspan="2">1</th><th colspan="2">2</th><th colspan="2">3</th></tr><tr><th>Measure</th><th>PD patients</th><th>HC</th><th>PD patients</th><th>HC</th><th>PD patients</th><th>HC</th></tr></thead><tbody><tr><td>Number</td><td>18</td><td>18</td><td>18</td><td>20</td><td>18</td><td>18</td></tr><tr><td>Gender (M/F)</td><td>15/3**</td><td>7/11</td><td>16/2***</td><td>5/15</td><td>11/7</td><td>11/7</td></tr><tr><td>Age</td><td>71.56 (2.06)</td><td>71.19 (2.52)</td><td>67.39 (2.10)</td><td>66.05 (2.05)</td><td>69.11 (1.44)</td><td>71.61 (2.05)</td></tr><tr><td>Years Education</td><td>13.50 (0.66)</td><td>12.93 (0.89)</td><td>14.83 (0.91)</td><td>13.75 (0.56)</td><td>11.94 (0.52)*</td><td>14.72 (0.65)</td></tr><tr><td>MoCA</td><td>29.44 (0.12)</td><td>29.63 (0.13)</td><td>28.72 (0.50)*</td><td>26.85 (0.53)</td><td>27.61 (0.54)</td><td>26.78 (0.56)</td></tr><tr><td>DASS</td><td>21.71 (2.85)*</td><td>12.19 (2.76)</td><td>15.39 (2.54)</td><td>20.05 (5.50)</td><td>29.13 (4.53)**</td><td>10.44 (2.29)</td></tr><tr><td>&#8195;Depression</td><td>6.35 (0.81)**</td><td>2.88 (0.87)</td><td>4.94 (1.13)</td><td>5.55 (1.958)</td><td>7.13 (1.71)***</td><td>2.78 (0.75)</td></tr><tr><td>&#8195;Anxiety</td><td>7.88 (1.27)**</td><td>3.25 (0.88)</td><td>5.67 (0.84)</td><td>5.50 (1.80)</td><td>10.33 (1.58)***</td><td>2.61 (0.69)</td></tr><tr><td>&#8195;Stress</td><td>7.47 (1.41)</td><td>6.06 (1.32)</td><td>4.78 (1.09)</td><td>9.00 (2.02)</td><td>11.67 (1.73)**</td><td>5.06 (1.25)</td></tr><tr><td>BIS</td><td>14.94 (2.36)</td><td>15.31 (3.07)</td><td>53.50 (2.47)</td><td>51.90 (2.35)</td><td>53.56 (2.70)</td><td>51.00 (1.88)</td></tr><tr><td>LARS</td><td>&#8722;20.22 (1.36)***</td><td>&#8722;27.44 (1.24)</td><td>&#8722;23.50 (1.71)*</td><td>&#8722;30.00 (1.58)</td><td>&#8722;22.44 (2.06)*</td><td>&#8722;27.06 (1.16)</td></tr><tr><td>UPDRS ON</td><td>18.67 (2.69)</td><td/><td>18.78 (2.85)</td><td/><td>26.50 (2.73)</td><td/></tr><tr><td>UPDRS OFF</td><td>24.56 (3.41)***</td><td/><td>23.28 (2.97)</td><td/><td>30.44 (2.52)***</td><td/></tr><tr><td>Years since diagnosis</td><td>4.44 (1.21)</td><td/><td>4.39 (0.90)</td><td/><td>5.00 (1.02)</td><td/></tr><tr><td>Years since symptoms</td><td>5.18 (1.28)</td><td/><td>4.78 (0.86)</td><td/><td>6.44 (1.10)</td><td/></tr><tr><td>LDE (mg)</td><td>566.41 (61.18)</td><td/><td>543.70 (67.36)</td><td/><td>653.00 (93.96)</td><td/></tr><tr><td># levodopa/ dopamine agonists/both</td><td>12/1/5</td><td/><td>10/2/6</td><td/><td>10/0/8</td><td/></tr><tr><td># on XL meds</td><td>3</td><td/><td>10</td><td/><td>9</td><td/></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>MoCA=Montreal Cognitive Assessment, DASS=Depression, Anxiety and Stress Scale, BIS=Barratt Impulsivity Scale, LARS=Lille Apathy Rating Scale, UPDRS=Unified Parkinson&#8217;s Disease Rating Scale, LDE=Levodopa Dose Equivalence.</p></fn></table-wrap-foot></table-wrap>